Limits...
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus

The result of 6-minute walking distance changes from placebo, in PHIRST study modified from the results published in Galiè et al.142.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352681&req=5

fig10: The result of 6-minute walking distance changes from placebo, in PHIRST study modified from the results published in Galiè et al.142.

Mentions: The second major phase 3 clinical trials was carried out with tadalafil based on the encouraging outcome of the SUPER-1 results and published case reports. Affuso et al. reported on a middle-aged woman affected by idiopathic pulmonary arterial hypertension whose quality of life and exercise tolerance improved remarkably after a six-month course of treatment with the long-acting phosphodiesterase-5 inhibitor tadalafil.141 PHIRST study (Pulmonary Arterial Hypertension and Response to Tadalafil))142 was a 16-week, double-blind, placebo-controlled study, involving 405 patients with pulmonary arterial hypertension either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan. Patients were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40 mg dose met the pre-specified level of statistical significance (p < 0.01). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m), compared with 23 m (95% confidence interval,  − 2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening (p = 0.041), incidence of clinical worsening (68% relative risk reduction; p = 0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing (Figure 10).142


The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

The result of 6-minute walking distance changes from placebo, in PHIRST study modified from the results published in Galiè et al.142.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352681&req=5

fig10: The result of 6-minute walking distance changes from placebo, in PHIRST study modified from the results published in Galiè et al.142.
Mentions: The second major phase 3 clinical trials was carried out with tadalafil based on the encouraging outcome of the SUPER-1 results and published case reports. Affuso et al. reported on a middle-aged woman affected by idiopathic pulmonary arterial hypertension whose quality of life and exercise tolerance improved remarkably after a six-month course of treatment with the long-acting phosphodiesterase-5 inhibitor tadalafil.141 PHIRST study (Pulmonary Arterial Hypertension and Response to Tadalafil))142 was a 16-week, double-blind, placebo-controlled study, involving 405 patients with pulmonary arterial hypertension either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan. Patients were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily. Tadalafil increased the distance walked in 6 minutes in a dose-dependent manner; only the 40 mg dose met the pre-specified level of statistical significance (p < 0.01). In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m), compared with 23 m (95% confidence interval,  − 2 to 48 m) in patients on background bosentan therapy. Tadalafil 40 mg improved the time to clinical worsening (p = 0.041), incidence of clinical worsening (68% relative risk reduction; p = 0.038), and health-related quality of life. The changes in World Health Organization functional class were not statistically significant. The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing (Figure 10).142

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus